We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: Olezarsen
MedXY News
EnglishTag

Olezarsen

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Apolipoprotein C-III Inhibition and the Atherosclerosis Paradox: Lessons from the Essence-TIMI 73b Olezarsen Study
CardiologyatherosclerosisCardiology

Apolipoprotein C-III Inhibition and the Atherosclerosis Paradox: Lessons from the Essence-TIMI 73b Olezarsen Study

By MedXY|Apr 9, 2026

The Essence-TIMI 73b trial reveals that despite a 64% reduction in triglycerides and a 72% drop in remnant cholesterol via olezarsen, non-calcified coronary plaque volume remained unchanged over 12 months.

Olezarsen Significantly Lowers Triglycerides and Cuts Pancreatitis Risk in Severe Hypertriglyceridemia: CORE‑TIMI 72a/CORE2‑TIMI 72b Results
CardiologyhypertriglyceridemiaOlezarsen
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story

Olezarsen Significantly Lowers Triglycerides and Cuts Pancreatitis Risk in Severe Hypertriglyceridemia: CORE‑TIMI 72a/CORE2‑TIMI 72b Results

By MedXY|Nov 10, 2025

Two randomized trials found monthly olezarsen (50 mg and 80 mg) produced large, dose-dependent triglyceride reductions and a marked decrease in acute pancreatitis compared with placebo in patients with severe hypertriglyceridemia; higher do

Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia: Advances in Antisense Therapies for Triglyceride Reduction
CardiologyhypertriglyceridemiaOlezarsen

Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia: Advances in Antisense Therapies for Triglyceride Reduction

By MedXY|Oct 6, 2025

Olezarsen, a GalNAc-conjugated antisense oligonucleotide targeting APOC3 mRNA, significantly reduces triglyceride levels in moderate hypertriglyceridemia, offering a promising therapeutic advance with favorable safety in cardiovascular risk

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities